Message #59 From:
NewsBot Date: April 7, 2008 09:43:18 PM
Oscient Pharmaceuticals to Participate in the Roth Capital Partners 20th Annual OC Growth Conference
Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in
the Roth Capital Partners 20th Annual OC Growth
Conference on Thursday, February 21, 2008 in Dana Point, California. The
Company’s President and CEO, Steven Rauscher,
will provide an overview of the Company; highlight details on the recent
market performance of ANTARA®
(fenofibrate) capsules and FACTIVE®
(gemifloxacin mesylate) tablets in the U.S.; and discuss the Company's
recently announced results for fiscal year 2007, in which Oscient
recorded $80.0 million in revenues.
The presentation will begin at 8:30 AM PT (11:30 AM ET) on Thursday and
will be webcast through the Company’s website
at www.oscient.com. An archive of
the webcast will also be available for 90 days.
About Oscient Pharmaceuticals
Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical
company marketing two FDA-approved products in the United States; ANTARA®
(fenofibrate) capsules, a cardiovascular product and FACTIVE®
(gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is
indicated for the adjunct treatment of hypercholesterolemia (high blood
cholesterol) and hypertriglyceridemia (high triglycerides) in
combination with diet. FACTIVE is approved for the treatment of acute
bacterial exacerbations of chronic bronchitis and community-acquired
pneumonia of mild to moderate severity. Oscient promotes ANTARA and
FACTIVE through a nationwide sales force calling on primary care
physicians, cardiologists, endocrinologists and pulmonologists. The
Company also has a novel, late-stage antibiotic candidate, Ramoplanin,
for the treatment of Clostridium difficile-associated disease
(CDAD).
For important information regarding the safety and use of ANTARA and
FACTIVE, please see the full prescribing information available at www.antararx.com
and www.factive.com. For a complete
description of the risks associated with our business please refer to
the Company’s Annual Report on Form 10-K for
the fiscal year ending December 31, 2007 and in other filings that we
may make with the Securities and Exchange Commission from time to time.
Oscient Pharmaceuticals Corporation Investor Relations: Christopher
Taylor, 781-398-2466 or Media Relations: Sarah Emond,
781-398-2544
